Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2023-05-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之发行保荐书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) by 中信证券股份有限公司 for 金陵药业股份有限公司's 2023年度向特定对象发行A股股票 (2023 private placement of A shares). It contains detailed information about the securities issuance, including the sponsor institution, legal and regulatory compliance, shareholding structure, financial data, and the underwriting process. The document is a formal sponsorship letter related to a capital raising event (private placement of shares). It is not a general annual report, earnings release, or management discussion. It is not a proxy statement or voting result announcement. It is a detailed document supporting a capital issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content confirm it is the actual sponsorship document, not just an announcement or a brief notice. Hence, the classification is CAP with high confidence.
2023-05-29 Chinese
中信证券股份有限公司关于金陵药业股份有限公司2023年度向特定对象发行A股股票之上市保荐书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is a detailed listing sponsorship letter (上市保荐书) from CITIC Securities regarding Jinling Pharmaceutical Company's 2023 private placement of A shares. It includes extensive information about the issuer, the issuance plan, financial data, risk factors, and regulatory compliance. The document is not a general annual report or earnings release but a formal regulatory filing related to a capital raising event. It is not a brief announcement but a comprehensive document exceeding 15,000 characters, containing detailed financial and operational data, risk disclosures, and issuance terms. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on the company's fundraising and capital structure changes through a private placement of shares.
2023-05-29 Chinese
金陵药业股份有限公司董事会战略委员会工作细则修订对照表
Governance Information Classification · 95% confidence The document is a detailed comparison table showing amendments to the working rules of the Board of Directors' Strategic Committee of Jinling Pharmaceutical Co., Ltd. It discusses governance structure, committee responsibilities, and procedural changes. There is no financial data, earnings information, or regulatory filing references. The content focuses on internal governance and board committee rules, which aligns with Governance Information filings.
2023-05-29 Chinese
金陵药业股份有限公司监事会关于公司2023年度向特定对象发行A股股票相关事项的书面审核意见
Capital/Financing Update Classification · 95% confidence The document is a written supervisory board opinion regarding the company's 2023 issuance of A shares to specific investors. It discusses compliance with laws and regulations, fairness of pricing, feasibility of the issuance plan, use of raised funds, and related party transactions. The document is a formal review and approval statement by the supervisory board rather than a financial report or announcement of results. It is not an annual or interim report, earnings release, or investor presentation. It is also not a proxy solicitation or voting result announcement. The content focuses on capital raising activities and related approvals, indicating it is a Capital/Financing Update.
2023-05-29 Chinese
金陵药业关于2023年度向特定对象发行A股股票的审核问询函回复及相关申请文件更新的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Jinling Pharmaceutical Co., Ltd. regarding the company's response to an inquiry letter from the Shenzhen Stock Exchange about its application for a private placement of A shares. It mentions the submission of supplementary and revised application documents and the ongoing review process by regulatory authorities including the China Securities Regulatory Commission. The document is short (782 characters) and primarily serves as a disclosure notice about the status of the application and regulatory review, not the actual issuance of shares or detailed financial data. It does not contain financial statements or detailed report content but is an update on the capital raising process. Therefore, it fits best under Capital/Financing Update (CAP).
2023-05-29 Chinese
金陵药业关于2023年度向特定对象发行A股股票摊薄即期回报、填补措施及相关主体承诺（修订稿）的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jinling Pharmaceutical Co., Ltd. regarding the 2023 issuance of A shares to specific investors and the dilution of immediate returns, along with remedial measures and related commitments. It includes detailed analysis of the impact of the share issuance on financial metrics such as earnings per share and net asset returns, risk warnings, necessity and rationality of the issuance, use of raised funds, governance and internal control measures, and commitments from directors and controlling shareholders. The document references regulatory guidelines and laws related to capital market investor protection and fundraising. It is not a full financial report but a detailed announcement about a capital raising event and its implications, including commitments to mitigate dilution effects. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising activities and capital structure changes. The document length is over 6,000 characters and contains substantive financial impact analysis, not merely a brief notice or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP with high confidence.
2023-05-29 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.